Cargando…

Three-Tiered Risk Stratification Model to Predict Progression in Barrett's Esophagus Using Epigenetic and Clinical Features

BACKGROUND: Barrett's esophagus predisposes to esophageal adenocarcinoma. However, the value of endoscopic surveillance in Barrett's esophagus has been debated because of the low incidence of esophageal adenocarcinoma in Barrett's esophagus. Moreover, high inter-observer and sampling-...

Descripción completa

Detalles Bibliográficos
Autores principales: Sato, Fumiaki, Jin, Zhe, Schulmann, Karsten, Wang, Jean, Greenwald, Bruce D., Ito, Tetsuo, Kan, Takatsugu, Hamilton, James P., Yang, Jian, Paun, Bogdan, David, Stefan, Olaru, Alexandru, Cheng, Yulan, Mori, Yuriko, Abraham, John M., Yfantis, Harris G., Wu, Tsung-Teh, Fredericksen, Mary B., Wang, Kenneth K., Canto, Marcia, Romero, Yvonne, Feng, Ziding, Meltzer, Stephen J.
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2270339/
https://www.ncbi.nlm.nih.gov/pubmed/18382671
http://dx.doi.org/10.1371/journal.pone.0001890
_version_ 1782151731555074048
author Sato, Fumiaki
Jin, Zhe
Schulmann, Karsten
Wang, Jean
Greenwald, Bruce D.
Ito, Tetsuo
Kan, Takatsugu
Hamilton, James P.
Yang, Jian
Paun, Bogdan
David, Stefan
Olaru, Alexandru
Cheng, Yulan
Mori, Yuriko
Abraham, John M.
Yfantis, Harris G.
Wu, Tsung-Teh
Fredericksen, Mary B.
Wang, Kenneth K.
Canto, Marcia
Romero, Yvonne
Feng, Ziding
Meltzer, Stephen J.
author_facet Sato, Fumiaki
Jin, Zhe
Schulmann, Karsten
Wang, Jean
Greenwald, Bruce D.
Ito, Tetsuo
Kan, Takatsugu
Hamilton, James P.
Yang, Jian
Paun, Bogdan
David, Stefan
Olaru, Alexandru
Cheng, Yulan
Mori, Yuriko
Abraham, John M.
Yfantis, Harris G.
Wu, Tsung-Teh
Fredericksen, Mary B.
Wang, Kenneth K.
Canto, Marcia
Romero, Yvonne
Feng, Ziding
Meltzer, Stephen J.
author_sort Sato, Fumiaki
collection PubMed
description BACKGROUND: Barrett's esophagus predisposes to esophageal adenocarcinoma. However, the value of endoscopic surveillance in Barrett's esophagus has been debated because of the low incidence of esophageal adenocarcinoma in Barrett's esophagus. Moreover, high inter-observer and sampling-dependent variation in the histologic staging of dysplasia make clinical risk assessment problematic. In this study, we developed a 3-tiered risk stratification strategy, based on systematically selected epigenetic and clinical parameters, to improve Barrett's esophagus surveillance efficiency. METHODS AND FINDINGS: We defined high-grade dysplasia as endpoint of progression, and Barrett's esophagus progressor patients as Barrett's esophagus patients with either no dysplasia or low-grade dysplasia who later developed high-grade dysplasia or esophageal adenocarcinoma. We analyzed 4 epigenetic and 3 clinical parameters in 118 Barrett's esophagus tissues obtained from 35 progressor and 27 non-progressor Barrett's esophagus patients from Baltimore Veterans Affairs Maryland Health Care Systems and Mayo Clinic. Based on 2-year and 4-year prediction models using linear discriminant analysis (area under the receiver-operator characteristic (ROC) curve: 0.8386 and 0.7910, respectively), Barrett's esophagus specimens were stratified into high-risk (HR), intermediate-risk (IR), or low-risk (LR) groups. This 3-tiered stratification method retained both the high specificity of the 2-year model and the high sensitivity of the 4-year model. Progression-free survivals differed significantly among the 3 risk groups, with p = 0.0022 (HR vs. IR) and p<0.0001 (HR or IR vs. LR). Incremental value analyses demonstrated that the number of methylated genes contributed most influentially to prediction accuracy. CONCLUSIONS: This 3-tiered risk stratification strategy has the potential to exert a profound impact on Barrett's esophagus surveillance accuracy and efficiency.
format Text
id pubmed-2270339
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-22703392008-04-02 Three-Tiered Risk Stratification Model to Predict Progression in Barrett's Esophagus Using Epigenetic and Clinical Features Sato, Fumiaki Jin, Zhe Schulmann, Karsten Wang, Jean Greenwald, Bruce D. Ito, Tetsuo Kan, Takatsugu Hamilton, James P. Yang, Jian Paun, Bogdan David, Stefan Olaru, Alexandru Cheng, Yulan Mori, Yuriko Abraham, John M. Yfantis, Harris G. Wu, Tsung-Teh Fredericksen, Mary B. Wang, Kenneth K. Canto, Marcia Romero, Yvonne Feng, Ziding Meltzer, Stephen J. PLoS One Research Article BACKGROUND: Barrett's esophagus predisposes to esophageal adenocarcinoma. However, the value of endoscopic surveillance in Barrett's esophagus has been debated because of the low incidence of esophageal adenocarcinoma in Barrett's esophagus. Moreover, high inter-observer and sampling-dependent variation in the histologic staging of dysplasia make clinical risk assessment problematic. In this study, we developed a 3-tiered risk stratification strategy, based on systematically selected epigenetic and clinical parameters, to improve Barrett's esophagus surveillance efficiency. METHODS AND FINDINGS: We defined high-grade dysplasia as endpoint of progression, and Barrett's esophagus progressor patients as Barrett's esophagus patients with either no dysplasia or low-grade dysplasia who later developed high-grade dysplasia or esophageal adenocarcinoma. We analyzed 4 epigenetic and 3 clinical parameters in 118 Barrett's esophagus tissues obtained from 35 progressor and 27 non-progressor Barrett's esophagus patients from Baltimore Veterans Affairs Maryland Health Care Systems and Mayo Clinic. Based on 2-year and 4-year prediction models using linear discriminant analysis (area under the receiver-operator characteristic (ROC) curve: 0.8386 and 0.7910, respectively), Barrett's esophagus specimens were stratified into high-risk (HR), intermediate-risk (IR), or low-risk (LR) groups. This 3-tiered stratification method retained both the high specificity of the 2-year model and the high sensitivity of the 4-year model. Progression-free survivals differed significantly among the 3 risk groups, with p = 0.0022 (HR vs. IR) and p<0.0001 (HR or IR vs. LR). Incremental value analyses demonstrated that the number of methylated genes contributed most influentially to prediction accuracy. CONCLUSIONS: This 3-tiered risk stratification strategy has the potential to exert a profound impact on Barrett's esophagus surveillance accuracy and efficiency. Public Library of Science 2008-04-02 /pmc/articles/PMC2270339/ /pubmed/18382671 http://dx.doi.org/10.1371/journal.pone.0001890 Text en This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration which stipulates that, once placed in the public domain, this work may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. https://creativecommons.org/publicdomain/zero/1.0/ This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration, which stipulates that, once placed in the public domain, this work may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose.
spellingShingle Research Article
Sato, Fumiaki
Jin, Zhe
Schulmann, Karsten
Wang, Jean
Greenwald, Bruce D.
Ito, Tetsuo
Kan, Takatsugu
Hamilton, James P.
Yang, Jian
Paun, Bogdan
David, Stefan
Olaru, Alexandru
Cheng, Yulan
Mori, Yuriko
Abraham, John M.
Yfantis, Harris G.
Wu, Tsung-Teh
Fredericksen, Mary B.
Wang, Kenneth K.
Canto, Marcia
Romero, Yvonne
Feng, Ziding
Meltzer, Stephen J.
Three-Tiered Risk Stratification Model to Predict Progression in Barrett's Esophagus Using Epigenetic and Clinical Features
title Three-Tiered Risk Stratification Model to Predict Progression in Barrett's Esophagus Using Epigenetic and Clinical Features
title_full Three-Tiered Risk Stratification Model to Predict Progression in Barrett's Esophagus Using Epigenetic and Clinical Features
title_fullStr Three-Tiered Risk Stratification Model to Predict Progression in Barrett's Esophagus Using Epigenetic and Clinical Features
title_full_unstemmed Three-Tiered Risk Stratification Model to Predict Progression in Barrett's Esophagus Using Epigenetic and Clinical Features
title_short Three-Tiered Risk Stratification Model to Predict Progression in Barrett's Esophagus Using Epigenetic and Clinical Features
title_sort three-tiered risk stratification model to predict progression in barrett's esophagus using epigenetic and clinical features
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2270339/
https://www.ncbi.nlm.nih.gov/pubmed/18382671
http://dx.doi.org/10.1371/journal.pone.0001890
work_keys_str_mv AT satofumiaki threetieredriskstratificationmodeltopredictprogressioninbarrettsesophagususingepigeneticandclinicalfeatures
AT jinzhe threetieredriskstratificationmodeltopredictprogressioninbarrettsesophagususingepigeneticandclinicalfeatures
AT schulmannkarsten threetieredriskstratificationmodeltopredictprogressioninbarrettsesophagususingepigeneticandclinicalfeatures
AT wangjean threetieredriskstratificationmodeltopredictprogressioninbarrettsesophagususingepigeneticandclinicalfeatures
AT greenwaldbruced threetieredriskstratificationmodeltopredictprogressioninbarrettsesophagususingepigeneticandclinicalfeatures
AT itotetsuo threetieredriskstratificationmodeltopredictprogressioninbarrettsesophagususingepigeneticandclinicalfeatures
AT kantakatsugu threetieredriskstratificationmodeltopredictprogressioninbarrettsesophagususingepigeneticandclinicalfeatures
AT hamiltonjamesp threetieredriskstratificationmodeltopredictprogressioninbarrettsesophagususingepigeneticandclinicalfeatures
AT yangjian threetieredriskstratificationmodeltopredictprogressioninbarrettsesophagususingepigeneticandclinicalfeatures
AT paunbogdan threetieredriskstratificationmodeltopredictprogressioninbarrettsesophagususingepigeneticandclinicalfeatures
AT davidstefan threetieredriskstratificationmodeltopredictprogressioninbarrettsesophagususingepigeneticandclinicalfeatures
AT olarualexandru threetieredriskstratificationmodeltopredictprogressioninbarrettsesophagususingepigeneticandclinicalfeatures
AT chengyulan threetieredriskstratificationmodeltopredictprogressioninbarrettsesophagususingepigeneticandclinicalfeatures
AT moriyuriko threetieredriskstratificationmodeltopredictprogressioninbarrettsesophagususingepigeneticandclinicalfeatures
AT abrahamjohnm threetieredriskstratificationmodeltopredictprogressioninbarrettsesophagususingepigeneticandclinicalfeatures
AT yfantisharrisg threetieredriskstratificationmodeltopredictprogressioninbarrettsesophagususingepigeneticandclinicalfeatures
AT wutsungteh threetieredriskstratificationmodeltopredictprogressioninbarrettsesophagususingepigeneticandclinicalfeatures
AT fredericksenmaryb threetieredriskstratificationmodeltopredictprogressioninbarrettsesophagususingepigeneticandclinicalfeatures
AT wangkennethk threetieredriskstratificationmodeltopredictprogressioninbarrettsesophagususingepigeneticandclinicalfeatures
AT cantomarcia threetieredriskstratificationmodeltopredictprogressioninbarrettsesophagususingepigeneticandclinicalfeatures
AT romeroyvonne threetieredriskstratificationmodeltopredictprogressioninbarrettsesophagususingepigeneticandclinicalfeatures
AT fengziding threetieredriskstratificationmodeltopredictprogressioninbarrettsesophagususingepigeneticandclinicalfeatures
AT meltzerstephenj threetieredriskstratificationmodeltopredictprogressioninbarrettsesophagususingepigeneticandclinicalfeatures